Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Cyclerion Therapeutics, Inc. | tm206168d1_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Cyclerion Therapeutics, Inc. | tm206168d1_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Cyclerion Therapeutics, Inc. | tm206168d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Cyclerion Therapeutics, Inc. | tm206168d1_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - Cyclerion Therapeutics, Inc. | tm206168d1_ex21-1.htm |
| EX-4.1 - EXHIBIT 4.1 - Cyclerion Therapeutics, Inc. | tm206168d1_ex4-1.htm |
| 10-K - FORM 10-K - Cyclerion Therapeutics, Inc. | tm206168d1_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-230615) pertaining to 2019 Equity Incentive Plan, 2019 Employee Stock Purchase Plan, Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan, and Amended and Restated 2005 Stock Incentive Plan of Cyclerion Therapeutics, Inc. of our report dated March 12, 2020, with respect to the consolidated financial statements of Cyclerion Therapeutics, Inc included in this Annual Report (Form 10-K) for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 12, 2020